SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study
SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Seung-Kee Min, MD.PhD.
- Phone Number: +82.2-2072-0297
- Email: skminmd@snuh.org
Study Locations
-
-
-
Seoul, Korea, Republic of, 110-744
- Recruiting
- Seung-Kee Min,
-
Contact:
- Seung-Kee Min, MD.
- Phone Number: +82.2-2072-0297
- Email: skminmd@snuh.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult, >18 years old
- Angiographically-confirmed significant femoro-popliteal (FP) stenosis or occlusion by atherosclerosis
- Successful FP intervention; residual stenosis <30%
- Without significant residual inflow disease; Intact iliac artery inflow (with or without intervention of iliac or below knee arteries)
- patent outflow status; at least 1 arterial runoff in below knee arteries
- All kind of fem-pop intervention including POBA, stent, DCB, DES for TASC A~ D
Exclusion Criteria:
- At risk of hemorrhage, bleeding tendency or thrombophilia
- Acute limb ischemia / inflammatory arterial disease
- Contraindication or allergic to ASA, clopidogrel, Anplone
- Medication of warfarin
- Pregnancy, hepatic dysfunction, thrombocytopenia
- Previous FP bypass or intervention
- Impossible to stop clopidogrel before EVT
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Sarpogrelate SR 300mg + ASA
Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions. Other Name: Anplone SR |
Other Names:
|
|
Active Comparator: Clopidogrel + ASA
Clopidogrel is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions. Other Name: Plavix |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Restenosis rate (50%>) in 6 months by CT angiography
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Target lesion restenosis(TLR) in 6 months
Time Frame: 6 months
|
6 months
|
|
Major bleeding complication
Time Frame: 6 months
|
6 months
|
|
Ipsilateral major amputation
Time Frame: 6 months
|
6 months
|
|
All-cause mortality
Time Frame: 6 months
|
6 months
|
|
All adverse events
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Atherosclerosis
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Serotonin Agents
- Serotonin Antagonists
- Clopidogrel
- Sarpogrelate
Other Study ID Numbers
Other Study ID Numbers
- SAFE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.